2016-12-20T13:39:16-06:00 2016-06-30 KPMG LLP 345 PARK AVE NEW YORK NY 10154 990 2015-07-01 231907729 JDRF INTERNATIONAL % GARY CURTO C/O JDRF INT JDRF 2127859500 26 BROADWAY 15TH FL NEW YORK NY 10004 MARK GREENE CFO 6468734311 2017-02-01 true DEVIN L DUNCAN P01249521 2127859700 2015 2017-02-10 21:41:12Z DEREK RAPP 26 BROADWAY 14TH FLOOR NEW YORK NY 10004 271736374 false X www.jdrf.org X 1970 PA Accelerating life-changing breakthroughs to cure, prevent and treat Type 1 Diabetes and its complications. SEE SCHEDULE O 31 31 890 300000 120408 112437 198918214 196804267 0 0 5469902 6524427 1087541 1027088 205475657 204355782 72354198 75084432 0 0 74558032 74149309 339000 0 25623973 38879888 40245664 186131118 189479405 19344539 14876377 184040608 197093128 128561111 133197854 55479497 63895274 X ACCELERATING LIFE-CHANGING BREAKTHROUGHS TO CURE, PREVENT AND TREAT TYPE 1 DIABETES AND ITS COMPLICATIONS. SEE SCHEDULE O false false 75084432 75084432 RESEARCH FUNDING - FOR THE FY16 PERIOD ENDING JUNE 30, 2016, JDRF DIRECTLY FUNDED $75 MILLION IN RESEARCH GRANTS AND AGREEMENTS. FOR AN EXPANDED DESCRIPTION OF PROGRAM SERVICE ACTIVITIES RELATED TO DIRECT RESEARCH FUNDING, SEE SCHEDULE O 21188795 RESEARCH CONSORTIA - JDRF MAINTAINS AN IN-HOUSE TEAM OF SKILLED SCIENTIFIC, MEDICAL, POLICY AND GOVERNMENT RELATIONS PROFESSIONALS WHO PLAY A CRITICAL ROLE IN LEADING AND SUPPORTING THE RESEARCH STRATEGY AND DISBURSEMENT OF RESEARCH FUNDS FROM JDRF AND OTHERS. THESE PROFESSIONALS IDENTIFY, EVALUATE AND INFLUENCE GROUNDBREAKING RESEARCH AS WELL AS WORK WITH REGULATORY AND POLICY OFFICIALS TO ENSURE RESEARCH CAN PROCEED WITHOUT DELAY AND RESULTS ARE UNDERSTOOD BY HEALTHCARE DECISION MAKERS. SEE SCHEDULE O. 52293201 PUBLIC EDUCATION - JDRF EDUCATES THE PUBLIC ABOUT T1D AND ITS COMPLICATIONS. FOR AN EXPANDED DESCRIPTION OF PROGRAM SERVICE ACTIVITIES RELATED TO PUBLIC EDUCATION, SEE SCHEDULE O 148566428 true true false true false false false false false true true true false false true true false true false true true true false true true true false true false true false false false false false false false false true false false false true true false false false true X 608 6 true 890 true true true true IS DA NL false false false true true false false false true false X 31 31 false false true false false false false true true false true true true true true true true true true true true true AL AK AZ AR CA CO CT DE DC FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY X X GARY CURTO CO JDRF INT 2124797551 26 BROADWAY 1TH FL NEW YORK NY 10004 X KAREN CASE FY14-16 BOARD MEMBER 5.0 0.0 X 0 0 0 TOM CHAPMAN FY14-16 BOARD MEMBER 5.0 0.0 X 0 0 0 MATTHEW COHN FY14-16 BOARD MEMBER 3.0 0.0 X 0 0 0 REBECCA DAVIES FY14-16 BOARD MEMBER 3.0 0.0 X 0 0 0 MAARTEN DE GROOT FY15-17 BOARD MEMBER 3.0 0.0 X 0 0 0 CAROL OXENREITER FY14-16 CHAIR, RESEARCH 7.0 0.0 X 0 0 0 LORNE SHIFF FY15-17 BOARD MEMBER 5.0 0.0 X 0 0 0 NICOLE JOHNSON FY16-18 BOARD MEMBER 3.0 0.0 X 0 0 0 MIKE LEE FY16-18 CHAIR, DEVELOPMENT 7.0 0.0 X 0 0 0 PREETISH NIJHAWAN FY16-18 BOARD MEMBER 3.0 0.0 X 0 0 0 LARRY SOLER FY16-18 SECRETARY/CHAIR NOMINATING 7.0 0.0 X X 0 0 0 WENDY WOOD FY16-18 BOARD MEMBER 5.0 0.0 X 0 0 0 NANETTE DETURK FY14-16 CHAIR, TALENT & COMPENSATION 7.0 0.0 X 0 0 0 MICHELLE GRIFFIN FY14-16 CHAIR, AUDIT 7.0 0.0 X 0 0 0 JOHN BRADY FY14-16 CHAIRMAN OF THE BOARD 20.0 0.0 X X 0 0 0 STEPHEN NEWMAN MD FY14-16 VICE CHAIRMAN OF THE BOARD 12.0 0.0 X X 0 0 0 TIMOTHY ST CLAIR FY14-16 BOARD MEMBER 3.0 0.0 X 0 0 0 LISA ALTMAN FY15-17 BOARD MEMBER 3.0 0.0 X 0 0 0 GRANT BEARD FY15-17 BOARD MEMBER 3.0 0.0 X 0 0 0 RANDY ANDERSON FY15-17 BOARD MEMBER 3.0 0.0 X 0 0 0 TIMOTHY CLARK FY15-17 CHAIR, INVESTMENT 7.0 0.0 X 0 0 0 MARK FISCHER-COLBRIE FY16-18 TREASURER / CHAIR OF FINANCE 7.0 0.0 X X 0 0 0 SCOTT MCCORMICK FY15-17 BOARD MEMBER 3.0 0.0 X 0 0 0 LISA REED FY15-17 BOARD MEMBER 3.0 0.0 X 0 0 0 RED MAXWELL FY15-17 BOARD MEMBER 3.0 0.0 X 0 0 0 MARVIN DAITCH FY16-18 BOARD MEMBER 3.0 0.0 X 0 0 0 PAM EDMONDS FY16-18 CHAIR, ADVOCARY 7.0 0.0 X 0 0 0 PAT MCFEELEY FY16-17 CHAIR, CHANCELLORS 7.0 0.0 X 0 0 0 JEFF PLUMER FY16-18 BOARD MEMBER 3.0 0.0 X 0 0 0 LORRAINE STIEHL FY15-17 BOARD MEMBER 3.0 0.0 X 0 0 0 LISA WALLACK FY16-18 BOARD MEMBER 3.0 0.0 X 0 0 0 DEREK RAPP PRESIDENT AND CEO 50.0 0.0 X 848349 0 23767 SANDRA HIJIKATA CHIEF DEVELOPMENT OFFICER 50.0 0.0 X 400312 0 17674 MARK GREENE CFO & ASST. TRES 50.0 0.0 X 380896 0 25583 JILL CLARK VP STRATEGIC INITIATIVES 50.0 0.0 X 228893 0 13742 JULIA GREENSTEIN VP RESEARCH 50.0 0.0 X 289093 0 17674 AARON KOWALSKI CHIEF MISSION OFFICER 50.0 0.0 X 309461 0 39885 RICHARD INSEL CHIEF SCIENTIFIC OFFICER 50.0 0.0 X 586842 0 39887 MARGO LUCERO SVP CORPORATE DEVELOPMENT 50.0 0.0 X 307224 0 39887 STEVEN GRIFFEN MD SVP RESEARCH 50.0 0.0 X 344677 0 39887 JEFFREY BREWER PRESIDENT AND CEO, ENDED 7/14 0.0 0.0 X 371875 0 0 EDWARD SEBALD CFO & ASST. TRES, ENDED 6/14 0.0 0.0 X 116417 0 0 GERRI BOSTICK CHIEF HR OFFICER, ENDED 6/14 50.0 0.0 X 278033 0 17674 4462072 0 275660 150 true true false BLACKBAUD 2000 DANIEL ISLAND DRIVE CHARLESTON SC 29492 FUNDRAISING SYSTEMS 1953995 HICKORY PRINTING SOLUTIONSLLC PO Box 69 HICKORY NC 28603 PRINTING CONSULTANT 1129899 SIX DEGREES MEDICAL 175 BLOOR ST TORONTO 0 CA PUBLIC ED CONSULTANT 1823750 THE PURSUANT GROUP 25 BROADWAY 9TH FLOOR NEW YORK NY 10004 FUNDRAISING CONSULT 2374120 10 UP LLC 2765 CARRADALE DRIVE ROSEVILLE CA 95661 IT CONSULTANT 467456 42 4403865 125353822 67046580 16921832 196804267 0 560787 95408 465379 0 0 0 0 0 46292000 40328360 5963640 5963640 5963640 26852177 125353822 26852177 0 1107374 200055 907319 907319 0 MISCELLANEOUS PROGRAM REVENUE 900099 119769 25000 94769 119769 204355782 120408 7431107 51193650 51193650 0 23890782 23890782 0 1752486 1118086 227823 406577 0 57456050 36656960 7469287 13329803 1421832 907129 184838 329865 9162639 5845764 1191143 2125732 4356302 2779321 566319 1010662 5287074 4467578 264354 555142 543913 459606 27196 57111 234228 197923 11711 24594 698569 590291 34928 73350 0 452230 452230 0 4395991 2325479 400035 1670477 1606866 850032 146225 610609 4081180 2485439 710125 885616 0 8701483 5402506 1670834 1628143 2444982 1782392 232273 430317 0 2910449 2121717 276493 512239 0 0 4614886 2810466 802990 1001430 533102 324659 92760 115683 OUTREACH EXPENSES 1425595 898125 201009 326461 DUES & FEES 1530483 964204 215798 350481 OTHER MISC EXPENSES 784633 494319 110633 179681 189479405 148566428 15289004 25623973 X 2095224 756210 127643 1211372 8000321 30314175 29714230 34391736 28204025 25415000 11684316 15598016 0 0 0 0 0 0 0 0 3783235 4604817 30476192 16886457 16473934 13589735 33715865 34442190 49699118 36283061 2487658 2454398 0 0 277906 0 184040608 197093128 13891579 16335885 105160199 105778368 6691858 8340978 0 0 0 0 0 0 0 0 0 0 2817475 2742623 128561111 133197854 X 17142205 24131379 31263491 32690094 7073801 7073801 55479497 63895274 184040608 197093128 14876377 -6460600 X false true X true false X 195105087 196010663 210068935 198918214 196804267 996907166 0 0 195105087 196010663 210068935 198918214 196804267 996907166 7810416 989096750 2021356 2015080 1646615 987577 465379 7136007 35418 29449 6810 2516 112437 186630 117723 74636 136667 256146 119769 704941 1004934744 0.98424 0.98688 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false true true false true 8887 true 2941 true 555 true 396845 true 451554 false 860782 false JDRF LOBBYING ACTIVITIES FORM 990- SCH-C- GENERAL STATEMENT OF ACTIVITIES JDRF is the leading global organization focused on type 1 diabetes (T1D) research. Driven by passionate, grassroots volunteers connected to children, adolescents, and adults with T1D, the goal of JDRF is to create a world without T1D. Through research and advocacy, JDRF is accelerating progress on the most promising opportunities to cure, treat, and prevent T1D. JDRF's advocacy includes lobbying activity to ensure Congress continues to invest in critically important medical research and puts in place policies to advance the discovery, development, and delivery of better therapies for T1D. JDRF staff and volunteers communicate with government officials through email, phone calls, and meetings, to educate them on issues and encourage the advancement of legislation. 7141514 37913 3000 7176427 7426222 11292 296000 7141514 6837461 625761 37000 7426222 6728240 100000 9221 6837461 5455024 1227000 179110 132894 6728240 0.98580 0.01420 false false 4721932 2702896 2019036 25754260 14183561 11570699 13589735 HEDGE FUNDS 20886476 F US-NON-PUBLIC INVESTMENT FUNDS 15396585 F 36283061 0 SPLIT INTEREST CHRT RMDR TRUST 2742623 2742623 X 197442952 -6460600 -6460600 203903552 452230 452230 204355782 189027175 189027175 452230 452230 189479405 ORGANIZATION'S ENDOWMENT FUNDS FORM 990, PART X, LINE 28 & 29 & SCH D, PART V THE INTENDED USE OF THE ORGANIZATION'S ENDOWMENT FUNDS IS TO USE THE FUNDS FOR BOTH SPECIFIC PROJECTS AS WELL AS SUPPORTING THE ORGANIZATION'S GENERAL EXEMPT PURPOSE. INCOME TAX POSITION OF JDRF INT. 990 SCH-D, PART X, LINE 2 JDRF is a not for profit organization exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code and is organized under the laws of the Commonwealth of Pennsylvania. The effect of income tax positions is recognized only if those positions are more likely than not of being sustained. Income generated from activities unrelated to JDRF's exempt purpose is subject to tax under Internal Revenue Code Section 511. Unrelated Business Income Tax liability was insignificant for the years ending June 30, 2016 and 2015. true North America Grantmaking RESEARCH GRANTS 3602196 Europe (Including Iceland and Greenland) Grantmaking RESEARCH GRANTS 15748328 Middle East and North Africa Grantmaking RESEARCH GRANTS 904943 East Asia and the Pacific Grantmaking RESEARCH GRANTS 3635315 Central America and the Caribbean Investments INVESTMENTS 7883322 Europe (Including Iceland and Greenland) 1 1 Program Services RESEARCH ADMINSTRATION 310350 1 1 1 1 32084454 32084454 East Asia and the Pacific 500248 CHECK/WIRE N/A N/A North America 84967 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 85604 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 1107939 CHECK/WIRE N/A N/A Middle East and North Africa 604943 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 204690 CHECK/WIRE N/A N/A East Asia and the Pacific 503712 CHECK/WIRE N/A N/A East Asia and the Pacific 647910 CHECK/WIRE N/A N/A East Asia and the Pacific IMMUNE THERAPIES 109286 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 167431 CHECK/WIRE N/A N/A East Asia and the Pacific 366034 CHECK/WIRE N/A N/A North America 371778 CHECK/WIRE N/A N/A North America 910685 CHECK/WIRE N/A N/A North America IMMUNE THERAPIES 464420 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) IMMUNE THERAPIES 113012 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) IMMUNE THERAPIES 392055 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 199941 CHECK/WIRE N/A N/A North America 437974 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 246031 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 196293 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) IMMUNE THERAPIES 100000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) IMMUNE THERAPIES 280011 CHECK/WIRE N/A N/A East Asia and the Pacific 89116 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 388837 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) IMMUNE THERAPIES 406440 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) IMMUNE THERAPIES 300000 CHECK/WIRE N/A N/A North America IMMUNE THERAPIES 535904 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 184651 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) GLUCOSE CONTROL 113012 CHECK/WIRE N/A N/A East Asia and the Pacific 603778 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 334961 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) IMMUNE THERAPIES 144203 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) IMMUNE THERAPIES 448624 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 789737 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 533696 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 119993 CHECK/WIRE N/A N/A North America 242280 CHECK/WIRE N/A N/A East Asia and the Pacific ARTIFICIAL PANCREAS 200000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 321225 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 193261 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 175991 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 451725 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 200000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 2808551 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 79484 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 58660 CHECK/WIRE N/A N/A East Asia and the Pacific 250000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 150000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 561994 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 303415 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) BETA CELL 156250 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) PREVENTION 90787 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) IMMUNE THERAPIES 253478 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) BETA CELL 65231 CHECK/WIRE N/A N/A North America REGENERATION 250000 CHECK/WIRE N/A N/A North America COMPLICATIONS 104188 CHECK/WIRE N/A N/A Middle East and North Africa REGENERATION 300000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) REGENERATION 55014 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) IMMUNE THERAPIES 56506 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) BETA CELL 356250 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) ARTIFICAL PANCREAS 1140000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) REGENERATION 180000 CHECK/WIRE N/A N/A East Asia and the Pacific IMMUNE THERAPIES 365231 CHECK/WIRE N/A N/A North America IMMUNE THERAPIES 200000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) IMMUNE THERAPIES 109991 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) IMMUNE THERAPIES 326009 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) IMMUNE THERAPIES 574729 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) IMMUNE THERAPIES 112616 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) IMMUNE THERAPIES 110000 CHECK/WIRE N/A N/A 69 true false true true false false GRANT MONITORING PROCEDURES SCH-F PART I LINE 2 Research grants are awarded by the recommendations of a professional scientific staff at JDRF based on input from outside scientific reviewers and patient advocates. The following areas are evaluated: (1) The scientific merit of the application. (2) The relationship of the research to the causes, treatment, prevention and cure of diabetes and its complications. Also considered are the merits of the institutions and/or sponsors of the applicant, and the applicant's commitment to the continuing diabetes research programs. JDRF staff reviews expenditures reported by an institution. X X X X X true Insurance Auto Auctions 3755 OMEC CIRCLE RANCHO CORDOVA CA 95742 CAR DONATION true 155969 63754 92215 155969 63754 92215 AL AK AZ AR CA CO CT DE DC FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY ILLINOIS WALK 4170099 437636 3732463 0 103625 0 9521 40561 8519 ILLINOIS GALA 4098127 686043 3412084 0 561 37281 254774 296911 8590 398 143937773 124230143 19707630 0 1529894 3078534 3058712 4912857 13511837 152205999 125353822 26852177 0 1634080 3115815 3323007 5250329 13528946 26852177 1107374 50000 150055 false 1107374 50000 150055 200055 907319 AL AZ AR CA CO CT DE DC FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY true false false false 1.00000 GARY CURTO 26 BROADWAY-14TH FLOOR NEW YORK NY 10004 false GARY CURTO TAX MANAGER -JDRF 0 FILING GAMING APPLICATIONS AND REPORTS X true 907319 SCHEDULE G, PART I, LINE 2 INSURANCE AUTO AUCTIONS LLC IS A THIRD PARTY CAR DONATION COMPANY THAT HANDLES ALL ASPECTS OF CARS BEING DONATED TO JDRF. THE PROGRAM RAISED $155,969 WITH TOTAL EXPENSES OF $63,754. A NET CHECK IS PAID DIRECTLY TO JDRF COVERING ALL EXPENSES AND FEES. TOTAL NET REVENUE FOR FY16 WAS $92,215. INSURANCE AUTO AUCTIONS IS LOCATED AT 3755 OMEC CIRCLE, RANCHO CORDOVA, CA 95742 true BENAROYA RESEARCH INST AT VIRGINIA MASON 1201 9TH AVE SEATTLE WA 98101 910653422 501(C)3 2935281 N/A N/A BD TECHNOLOGIES DAVIS DRIVE RESEARCH TRIANGLE PK NC 27709 999999999 200000 N/A N/A BOSTON CHILDREN'S HOSPITAL 300 LONGWOOD AVE BOSTON MA 02115 042774441 501(C)3 798567 N/A N/A CAPILLARY BIOMEDICAL 56 HAVENWOOD IRVINE CA 92614 464787731 200000 N/A N/A IMMUNE THERAPIES EASTERN VIRGINIA MEDICAL SCHOOL 358 MOWBRAY ACH NORFOLK VA 23501 237053028 501(C)3 199734 N/A N/A ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BRONX NY 10461 237025620 501(C)3 110000 N/A N/A UNIVERSITY OF ARIZONA PO BOX 210 TUCSON AZ 85721 113661893 501(C)3 907241 N/A N/A DQ&A 804 HAIGHT STREET FRANCISCO CA 94117 264482454 67000 N/A N/A IMMUNE THERAPIES CORNELL UNIVERSITY 144 EAST AVE ITHACA NY 14850 150532082 501(C)3 124996 N/A N/A INDIANA UNIVERSITY 620 UNION DR INDIANAPOLIS IN 46202 356018940 501(C)3 692768 N/A N/A BETH ISRAEL MEDICAL CENTER 1 BROOKLINE AVE BOSTON MA 92121 135564934 501(C)3 253864 N/A N/A JOSLIN DIABETES CENTER 1 JOSLIN PL BOSTON MA 02215 042203836 501(C)3 1211331 N/A N/A EVIDERA INC 7101 WISCONSIN AVE BETHESDA MD 20814 999999999 776920 N/A N/A FOUNDATION FOR THE NATIONAL INST OF HEALTH 9650 ROCKVILLE PIKE BETHESDA MD 20814 271518433 501(C)3 100000 N/A N/A BETA CELL THERAPIES MASSACHUSETTS INSTITUTE OF TECHNOLOGY 25 AMES ST CAMBRIDGE MA 02467 042103594 501(C)3 353615 N/A N/A INDIANA BIOSCIENCES RES INST 345 W 16TH STREET INDIANAPOLIS IN 46202 462882271 150000 N/A N/A CALIFORNIA INST FOR BIOMEDICAL RESEARCH 11119 NTORRY PINES RD LAJOLLA CA 92037 956047739 501(C)3 1998150 N/A N/A EMORY UNIVERSITY 69 JESSE HILL JR DRIVE ATLANTA GA 30322 580566256 501(C)3 171395 N/A N/A IOWA STATE UNIVERSITY COLLEGE DRIVE AMES IA 50011 420933966 501(C)3 96265 N/A N/A IMMUNE THERAPIES GEORGIA TECH RESEARCH CORP 505 TENTH STREET ATLANTA GA 30332 580603146 501(C)3 690804 N/A N/A IMMUNE THERAPIES STANFORD UNIVERSITY 300 PASTEUR DR PALA ALTO CA 94305 941156365 501(C)3 889150 N/A N/A JOHNS HOPKINS UNIVERSITY 733 N BROADWAY BALTIMORE MD 21205 520595110 501(C)3 496623 N/A N/A IMMUNE THERAPIES NEW YORK UNIVERSITY SCHOOL OF MEDICINE 550 FIRST AVENUE NEW YORK NY 10016 135562309 501(C)3 199967 N/A N/A NATIONAL JEWISH HEALTH 601 EAST 18TH STREET DENVER CO 80206 742044647 501(C)3 400000 N/A N/A NORTH CAROLINA STATE UNIVERSITY 2701 SULLIVAN DRIVE RALEIGH NC 27695 440680117 501(C)3 540000 N/A N/A BECKMAN RESEARCH INST OF THE CITY OF HOPE 1500 EAST DUARTE ROAD DUARTE CA 91010 953432210 501(C)3 620696 N/A N/A LEXICON PHARMACEUTICALS 8800 TECH FOREST PL THE WOODLANDS TX 77381 760474189 400000 N/A N/A PACIFIC DIABETES TECHNOLOGIES 154 SW GARDEN PLACE PORTLAND OR 97223 999999999 501(C)3 272188 N/A N/A UNIVERSITY OF FLORIDA 1600 SW ARCHER ROAD GAINESVILLE FL 32610 590974739 501(C)3 3766423 N/A N/A UNIVERSITY OF MIAMI SCHOOL OF MEDICINE 1450 NW 10TH AVE MIAMI FL 33136 590624458 501(C)3 932849 N/A N/A UNIVERSITY OF VIRGINIA 104 MIDMONT LN CHARLOTTESVILLE VA 22902 416042488 501(C)3 143311 N/A N/A UNIVERSITY OF MICHIGAN 1331 EAST ANN STREET ANN ARBOR MI 48109 386006309 501(C)3 552956 N/A N/A UNIVERSITY OF PITTSBURGH E 1140 STARZL PITTSBURGH PA 15261 113708851 501(C)3 167544 N/A N/A UNIVERSITY OF CALIFORNIA 3333 CA ST SAN FRANCISCO CA 94122 956006143 501(C)3 6098335 N/A N/A UNIVERSITY OF WISCONSIN-MADISON 21 NORTH PARK MADISON WI 53706 396006492 501(C)3 844277 N/A N/A UT SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS TX 75390 756002868 501(C)3 550923 N/A N/A VANDERBILT UNIVERSITY MEDICAL CENTER 1211 MEDICAL CENTER DR NASHVILLE TN 37232 620476822 501(C)3 240120 N/A N/A BAYLOR COLLEGE OF MEDICINE-RESEARCH INSTITUTE 3500 GASTON AVE DALLAS TX 75246 751921898 501(C)3 234878 N/A N/A THE BROAD INSTITUTE OF HARVARD & MIT 7 CAMBRIDGE CENTER CAMBRIDGE MA 02142 263428781 501(C)3 758613 N/A N/A DUKE UNIVERSITY 4321 MEDICAL PARK DR DURHAM NC 27704 560532129 501(C)3 200000 N/A N/A JAEB CENTER FOR HEALTH RESEARCH FND 15310 Amberly Drive TAMPA FL 33647 593187624 501(C)3 1189074 N/A N/A VIACYTE 3550 GENERAL ATOMICS SAN DIEGO CA 92121 330884172 1000000 N/A N/A AZ BD OF REGENTS UNIVERSITY OF ARIZONA 811 N Euclid Ave Tucson AZ 85724 113661893 501(C)3 907241 N/A N/A UNIVERSITY OF ALABAMA COLLEGE DRIVE BIRMINGHAM AL 35294 636001138 501(C)3 1390613 N/A N/A MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 042697983 501(C)3 77308 N/A N/A NORTHWESTERN UNIVERSITY 633 CLARK STREET EVANSTON IL 60208 231352685 501(C)3 1031907 N/A N/A DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON MA 02115 042263040 501(C)3 252768 N/A N/A BETA CELL THERAPIES SELECTRA BIOSCIENCE INC 480 ARSENAL STREET WATERTOWN MA 02472 261622110 100000 N/A N/A THE UNIVERSITY OF CHICAGO 5801 SOUTH ELLIS AVE CHICAGO IL 60637 362177139 501(C)3 299864 N/A N/A ICAHN SCHOOL OF MEDICINE MOUNT SINAI 1 GUSTAVE L LEVY PLACE NEW YORK NY 10029 136171197 501(C)3 650787 N/A N/A NOVARTIS INSTITUTE-GENOMICS 10675 JOHN HOPKINS DR SAN DIEGO CA 92121 223610512 2000000 N/A N/A SANFORD RESEARCH 2301 E 60TH ST NORTH SIOUX FALLS SD 57104 460450378 258600 N/A N/A UNIVERSITY OF MINNESOTA 80 SOUTH 8TH STREET MINNEAPOLIS MN 55455 416007513 501(C)3 774974 N/A N/A JACKSON LABORATORY 600 MAIN STREET BAR HARBOR ME 04609 010211513 501(C)3 56620 N/A N/A RUTGERS THE STATE UNIVERSITY 175 UNIVERSITY AVE NEWARK NJ 07107 462354111 501(C)3 20000 N/A N/A IMMUNE THERAPIES THE UNIVERSITY OF OKLAHOMA 100 STANTON OKLAHOMA CITY OK 73104 736017987 501(C)3 60796 N/A N/A THERMALIN DIABETES 10000 CEDAR AVE CLEVELAND OH 44106 180057439 464782 N/A N/A UNIVERSITY OF WASHINGTON 1401 15TH AVE SEATTLE WA 98195 911486484 501(C)3 11708 N/A N/A UNIVERSITY OF ROCHESTER 500 JOESPH WILSON BLVD ROCHESTER NY 14611 160743209 501(C)3 165000 N/A N/A DIABETOMICS 2345 AMBERBROOK HILLSBORO OR 97006 273132477 150000 N/A N/A PREVENTION MICHIGAN STATE UNIVERSITY 426 AUDITORIUM LANSING MI 48901 386552713 501(C)3 307416 N/A N/A COMPLICATIONS OREGON STATE UNIVERSITY 308 KERR ROAD CORVALLIS OR 97331 611730890 501(C)3 56620 N/A N/A ARTIFICIAL PANCREAS SANFORD-BURNHAM MEDICAL 10901 NTORREY PINES RD LA JOLLA CA 92037 510197108 501(C)3 109999 N/A N/A COMPLICATIONS ILLINOIS INST OF TECHNOLOGY 300 S FEDERALSTREET CHICAGO IL 61801 376006007 501(C)3 50871 N/A N/A ENCAPSULATED ISLETS THE BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON MA 02108 042312909 501(C)3 359618 N/A N/A COMPLICATIONS THOMAS JEFFERSON UNIVERSITY 125 S 9TH STREET PHILADELPHIA PA 19019 232829095 501(C)3 14573 N/A N/A ARTIFICIAL PANCREAS TIDEPOOL 450 TOOWNSEND ST SAN FRANCISCO CA 94112 462302287 474960 N/A N/A ARTIFICIAL PANCREAS WAVE 80 BIOSCIENCES 2325 THIRD STREET SAN FRANCISCO CA 94102 999999999 120000 N/A N/A PREVENTION UNIVERSITY OF UTAH 201 PRESIDENTS CR SALT LAKE CITY UT 84101 876000525 501(C)3 250000 N/A N/A GLUCOSE MODULATION WAYNE STATE UNIVERSITY 5700 CASS AVE DETROIT MI 48201 383555142 501(C)3 262786 N/A N/A ENCAPSULATED ISLETS ALLEGHENY SINGER RESEARCH INST 320 E NORTH AVENUE PITTSBURGH PA 15212 251320493 250000 N/A N/A BETA CELL THRAPIES HARVARD MEDICAL SCHOOL 200 LONGWOOD AVE BOSTON MA 02115 042103580 501(C)3 2576381 N/A N/A IMMUNE THERAPIES PRODO LABORATORIES 27402 ALISO VIEJO PKY ALISO VIEJO CA 92656 205534494 163597 N/A N/A IMMUNE THERAPIES PROTOMER TECHNOLOGIES 430 S CATALINA AVE PASADENA CA 91106 474206994 380000 N/A N/A IMMUNE THERAPIES UNIVERSITY OF SOUTHERN CALIFORNIA COLLEGE DRIVE LOS ANGELES CA 90089 951642394 501(C)3 253409 N/A N/A IMMUNE THERAPIES UNIVERSITY OF COLORADO PO BOX 6511 DENVER CO 80045 846049811 501(C)3 2540591 N/A N/A IMMUNE THERAPIES RESEARCH TRIANGLE INSTITUTE 200 PARK OFFICES DRIVE DURHAM NC 27709 999999999 400000 N/A N/A IMMUNE THERAPIES UNIVERSITY OF ILLINOIS 1200 HARRISON CHICAGO IL 60612 376006007 501(C)3 300781 N/A N/A IMMUNE THERAPIES MEDICAL COLLEGE OF WISCONSIN 8701 WATERTOWN PLANK MILWAUKEE WI 53226 390806261 501(C)3 360000 N/A N/A IMMUNE THERAPIES OHIO STATE UNIVERSITY 1060 CARMACK ROAD COLUMBUS OH 43210 311145986 501(C)3 110000 N/A N/A IMMUNE THERAPIES BOSTON UNIVERSITY 44 CUMMINGTON STREET BOSTON MA 02215 042103547 501(C)3 249999 N/A N/A IMMUNE THERAPIES COLUMBIA UNIVERSITY PO BOX 276720 NEW YORK NY 10087 135598093 501(C)3 444331 N/A N/A IMMUNE THERAPIES UNIVERSITY OF PENNSYLVANIA 3451 WALNUT STREET PHILADELPHIA PA 19104 231352685 501(C)3 119696 N/A N/A IMMUNE THERAPIES UNITO 11 AVENUE DE LAYFETTE BOSTON MA 02111 451623549 1387020 N/A N/A IMMUNE THERAPIES UNIVERSITY OF MARYLAND COLLEGE PAR ROAD COLLEGE PARK MD 20737 522004514 501(C)3 249912 N/A N/A IMMUNE THERAPIES UNIVERSITY OF NEBRASKA 151 WHITTIER LINCOLN NE 68503 470379839 501(C)3 243814 N/A N/A IMMUNE THERAPIES UNIVERSITY OF TEXAS HEALTH SCIENCE 7703 FLOYD CURL DRIVE SAN ANTONIO TX 83929 741586031 501(C)3 83929 N/A N/A IMMUNE THERAPIES WASHINGTON UNIVERSITY One Brookings Drive St Louis MO 94107 430653611 501(C)3 499890 N/A N/A IMMUNE THERAPIES 69 19 GRANT MONITORING PROCEDURES SCH-I PART I LINE 2 Research grants are awarded by the recommendations of a professional scientific staff at JDRF based on input from outside scientific reviewers and patient advocates. The following areas are evaluated: (1) The scientific merit of the application. (2) The relationship of the research to the causes, treatment, prevention and cure of diabetes and its complications. Also considered are the merits of the institutions and/or sponsors of the applicant, and the applicant's commitment to the continuing diabetes research programs. JDRF staff reviews expenditures reported by an institution. X X true true X X X X X true false false false false false false true false JEFFREY BREWER PRESIDENT AND CEO, ENDED 7/14 0 0 0 0 371875 0 0 0 0 0 371875 0 0 0 DEREK RAPP PRESIDENT AND CEO 600000 0 135849 0 112500 0 0 0 23767 0 872116 0 0 0 JULIA GREENSTEIN VP RESEARCH 270491 0 18602 0 0 0 16120 0 1554 0 306767 0 0 0 AARON KOWALSKI CHIEF MISSION OFFICER 288461 0 21000 0 0 0 16120 0 23765 0 349346 0 0 0 SANDRA HIJIKATA CHIEF DEVELOPMENT OFFICER 357917 0 42395 0 0 0 16120 0 1554 0 417986 0 0 0 MARK GREENE CFO & ASST. TRES 354375 0 26521 0 0 0 16120 0 9463 0 406479 0 0 0 RICHARD INSEL CHIEF SCIENTIFIC OFFICER 501667 0 35175 0 50000 0 16120 0 23767 0 626729 0 0 0 JILL CLARK VP STRATEGIC INITIATIVES 219832 0 9061 0 0 0 13259 0 483 0 242635 0 0 0 MARGO LUCERO SVP CORPORATE DEVELOPMENT 263333 0 43891 0 0 0 16120 0 23767 0 347111 0 0 0 STEVEN GRIFFEN MD SVP RESEARCH 323733 0 20944 0 0 0 16120 0 23767 0 384564 0 0 0 EDWARD SEBALD CFO & ASST. TRES, ENDED 6/14 0 0 0 0 116417 0 0 0 0 0 116417 0 0 0 GERRI BOSTICK CHIEF HR OFFICER, ENDED 6/14 263813 0 14220 0 0 0 16120 0 1554 0 295707 0 0 0 HOUSING ALLOWANCE SCHEDULE J PART I, LINE 1A Dr. Insel, highest compensated employee, received a housing allowance that was grossed up as per the terms of his employment agreement. For the 2015 calendar year, the housing allowance provided to Dr. Insel was $50,000; such amount was treated as taxable compensation and included in his Form W-2. This amount was also reported on Schedule J, Part II, Col. (B)(iii). OTHER REPORTABLE COMPENSATION SCHEDULE J PART II, COL (B)(iii) DEREK RAPP, RECEIVED RELOCATION EXPENSES FOR THE 2015 CALENDAR YEAR, THE ALLOWANCE PROVIDED TO MR. RAPP WAS $112,500; SUCH AMOUNT WAS TREATED AS TAXABLE COMPENSATION AND INCLUDED IN HIS FORM W-2. THIS AMOUNT WAS ALSO REPORTED ON SCHEDULE J, PART II, COL (B)(iii). NON-FIXED PAYMENTS FORM 990, SCHEDULE J, PART I, LINE 7 JDRF AWARDS NON-FIXED PAYMENTS SUCH AS BONUSES ON A DISCRETIONARY BASIS TIED TO THE EMPLOYEES PERFORMANCE. THE NAMES OF EMPLOYEES AND THE AMOUNTS THAT WERE PAID ARE FOUND ON SCHEDULE J, PAGE 2, PART II, COL. (B) (II). SEVERANCE PAYMENTS SCHEDULE J, PART I, LINE 4A JEFFREY BREWER RECEIVED A SEVERANCE PAYMENT OF $371,875 WHICH IS REPORTED ON SCHEDULE J, PART II COL. (B)(III) OTHER REPORTABLE COMPENSATION. MR. BREWER'S LAST DATE OF EMPLOYMENT AS PRESIDENT AND CEO WAS JULY 21, 2014. EDWARD SEBALD RECEIVED A SEVERANCE PAYMENT OF $116,417 WHICH IS REPORTED ON SCHEDULE J, PART II COL. (B)(III) OTHER REPORTABLE COMPENSATION. MR. SEBALD'S LAST DATE OF EMPLOYMENT WAS AUG 21, 2014. X 4 150055 TICKET SALES X 308 4497842 NET PROCEEDS OF SALE X MISC AUCTION ITEMS DONATED 10000 12273935 THRIFT SHOP 1 false true true THIRD PARTY ASSISTANCE LINE 32B INSURANCE AUTO AUCTIONS LLC IS A THIRD PARTY CAR DONATION COMPANY THAT HANDLES ALL ASPECTS OF CARS BEING DONATED TO JDRF. DONORS CALL A TOLL FREE NUMBER AND THEY ARE PUT IN CONTACT WITH A TOWING SERVICE IN THEIR AREA. AFTER THE CAR IS DONATED, INSURANCE AUTO AUCTIONS HANDLES ALL IRS 1098-C REPORTING. INSURANCE AUTO AUCTIONS IS A LICENSED PROFESSIONAL FUNDRAISER AND IS LICENSED IN THE STATES THAT REQUIRE IT TO REGISTER. FOR THE PERIOD ENDING 6/30/16, THE CAR PROGRAM LLC RAISED $155,969 WITH TOTAL EXPENSES OF $63,754. A NET CHECK IS PAID DIRECTLY TO JDRF. JDRF DOES NOT PAY INSURANCE AUTO AUCTIONS ANY EXPENSES OR FEES DIRECTLY. TOTAL NET REVENUE FOR FY-16 WAS $92,215. NONCASH CONTRIBUTIONS FORM 990, SCHEDULE M, PAGE 1 TYPES OF PROPERTY AND THE AMOUNTS LISTED IN PART I LINES 6 & 9 ARE THE ACTUAL AMOUNT THAT DONORS HAVE DONATED FOR VEHICLES AND SECURITIES. LINE 25 COLUMN(b), IS AN ESTIMATE OF MISC ITEMS THAT ARE SOLD AT VARIOUS AUCTIONS & RAFFLES. ORGANIZATION'S MISSION FORM 990, PART III, LINE 1 JDRFs mission is to accelerate life-changing breakthroughs to cure, prevent and treat Type 1 Diabetes (T1D) and its complications. JDRF is the leading global organization focused on T1D research and is committed to funding the development of new therapies and treatments to keep people with T1D healthier, longer, until a cure is found. Its strength lies in its exclusive focus and singular influence on the worldwide effort to end T1D. JDRF works every day to change the reality of this life-threatening autoimmune disease for millions of people - and to prevent anyone else from contracting the disease - by funding research, advocating for government support of research and new therapies, ensuring new therapies and technologies come to market, and connecting and engaging the T1D community. JDRF has funded more than $2 billion in research to date and made significant progress in understanding and fighting the disease. JDRF has played a role in nearly every T1D therapeutic advance of the past four decades, including the FDA-approved hybrid closed-loop artificial pancreas system in September 2016. PART III: STATEMENT OF PROGRAM SERVICE ACCOMPLISHMENTS LINE 4A ($75,084,432) RESEARCH FUNDING JDRF funds research with the greatest potential to cure, prevent and treat type 1 diabetes (T1D). Its strength lies in its exclusive focus and singular influence on the worldwide effort to end T1D. JDRF has committed more than $2 billion to this research since 1970. The full impact of JDRFs research investment extends well beyond direct funding. JDRF leverages partnerships with academia, industry and clinicians to ensure that the most promising research opportunities are funded and accelerated. JDRF often provides early stage funding to research projects, and the results of those projects often lead to follow-on participation from many other entities--both other non-for-profit funders and corporations. JDRF's research team is staffed by accomplished experts and leaders in the field of T1D science and medicine who guide the organization's funding efforts every step of the way. JDRFs highest priority remains funding research to deliver a cure for T1D and its complications. At the same time, JDRF is focused on developing better treatments that will transform the way people with T1D treat the disease today to help them live healthier lives now and in the future. The foundation's diversified research portfolio includes the following therapy areas: Artificial Pancreas: Artificial pancreas systems use technology to replicate the operation of a normal human pancreas and are one of the most revolutionary advances in diabetes care since the discovery of insulin. These systems link continuous glucose monitors and insulin pumps to smart software so that the right amount of insulin is delivered at the right time. Glucose Control: Glucose-responsive insulins(GRIs)--or smart insulins--promise to be a game-changer in blood-sugar management. GRIs will be the first-ever insulin formulation that turns on and off in response to blood sugar highs and lows. JDRF is also funding research that explores the benefits of combining novel or repurposed drugs with standard insulin therapy. Beta Cell Replacement: This therapy, also known as encapsulation, can be implanted to provide long-term relief from insulin dosing without the need for immune suppression. JDRF-supported scientists are improving biomaterials for encapsulation devices to protect implanted beta cells from autoimmune attack, among other strategies. Beta Cell Restoration: This drug or biologic-based therapy represents a full biological cure for people with T1D. It stimulates restoration of the bodys own beta cells and the capacity to produce insulin. We are repurposing drugs that may reduce beta cell stress and/or induce survival, as well as funding immune therapies that will stop the disease in its tracks. Complications: JDRF-funded research has already yielded new treatments for diabetic eye and kidney disease, the most common complications. Today, researchers are identifying biomarkers and accelerating the completion of clinical trials of potential treatments. Prevention: JDRF research has identified a number of potential triggers, including viruses and environmental conditions, which could open the door to new vaccines and other prevention strategies. The organization is also funding efforts to stall the progression of the disease in those at risk or newly diagnosed. For more information, visit jdrf.org/research. LINE 4B ($21,188,795) RESEARCH CONSORTIA JDRF maintains an in-house team of skilled scientific, policy and government relations professionals with credentials, including PhD.'s, MD's, MBAs, MAs, and others, each of whom plays a critical role in leading and supporting the research strategy and the disbursement of research funds from JDRF and others to create a world without type 1 diabetes (T1D). In their respective responsibilities, these professionals perform the functions of identifying, evaluating and influencing groundbreaking research being funded by JDRF, other foundations, governments and industry to achieve the organization's mission. These professionals also work with regulatory and policy officials to ensure research can proceed without delay and that research results are well understood by healthcare decision makers. As part of these efforts, JDRF organizes and funds scientific meetings, symposia, and conferences with the purpose of reviewing research proposals, ensuring that JDRF's research strategy is well aligned with the needs of the T1D community and allowing JDRF to provide scientific updates on the research it manages. JDRF also works with its external Research Advisory Committee (RAC), which is composed of professionals who are internationally renowned for their expertise in research as well as the care and treatment of those with T1D. The RAC advises on matters of policy pertaining to research philosophy and procedures to help the organization be most effective. All of this work to convene the best minds in the field enhances JDRF's ability to forecast future scientific direction, to judge the potential efficiency and effectiveness of new pathways and to identify gaps where JDRF can focus its funding to make the most impact. It is from this position of strength that JDRF identified opportunities where the Foundation can make significant advances in the near future and launched a five-year strategic plan in 2015 to accelerate progress to cure, prevent and treat T1D and its complications LINE 4C ($52,293,201) PUBLIC EDUCATION Because of its leading role in type 1 diabetes (T1D) research globally, JDRF is in a unique position to provide public education about diabetes and its complications. JDRF's efforts impact not only the millions of people with the disease and their families and the general public, but also those at risk for developing the disease. Type 1 diabetes strikes both children and adults suddenly, and the adjustment period following a diagnosis can be overwhelming. JDRF educates people about the warning signs of T1D, which can be profoundly helpful in ensuring timely diagnoses and reducing the potential, short-term, catastrophic consequences of T1D. The foundation provides outreach services and resources, like the JDRF Bag of Hope and the JDRF Adult T1D Care Kit, for newly diagnosed children and adults, respectively, and toolkits for managing all ages and stages of life with T1D. JDRF also provides information and updates about current research directions and progress and about human clinical trials that are seeking participants (including through JDRF's Clinical Trials Connection matching tool: www.jdrf.org/research/clinical-trials). Through all of its U.S. chapters and online, JDRF supports the T1D communitys diverse needs, connecting people with local support, expert resources and the worldwide effort to end this serious disease. CONFLICT OF INTEREST POLICY FORM 990- PART VI-SECT B, LINE 12C All officers, directors, key employees, board and committee members (both chapters and international boards) are required to sign a conflict of interest policy annually and disclose any conflicts. The Office of the President and CEO manages this process, and JDRF's internal audit department annually audits to ensure compliance. If any conflict does arise, the board members with the conflicts will recuse themselves from the meeting and/or vote. PUBLIC DOCUMENTS FORM 990, PAGE 6, PART VI, SECTION C, LINE 19 The organization makes its governing documents, conflict of interest policy and financial statements available to the public on its website: www.JDRF.org. The public may access copies of JDRF's W-9, annual reports, 990 tax returns, 501(c)(3) IRS letter, and audited financials, at the following link: www.jdrf.org/about/financials EXECUTIVE COMPENSATION POLICY PART VI, SECTION B, LINES 15a & 15b JDRFs Board of Directors charges a Talent and Compensation Committee to develop and recommend a compensation philosophy that applies to all employees of JDRF, including recommendations regarding the compensation and benefits of JDRF senior management for approval by the Executive Committee. The Committee works in collaboration with the President and CEO and the Chief People Officer and other senior staff personnel in the JDRF Human Resources Department to ensure that 1) the Foundations talent strategy supports and is aligned with its overall organization strategies; 2) JDRF is in compliance with IRS guidelines for determining reasonableness in pay practices; and 3) overall compensation for JDRFs key executives is competitive and aligned with pay philosophy. To attract and retain top scientific and executive talent to advance its mission, the organization pays competitive and appropriate salaries as determined by analysis of reliable data and input from independent third-party consultants. The review of JDRF executive compensation and benefits under the procedures noted above is completed annually by the Compensation Committee, and the basis for their determination are documented contemporaneously in the minutes of the Committees meetings, including most recently on December 4, 2015. 990 REVIEW PROCESS FORM 990 SECTION B, PART VI, QUESTION 11B JDRF has a rigorous standard approach to reviewing its 990. The Organization's Tax Manager works with its outside tax professionals to prepare the return and all supporting schedules. The draft return is reviewed by a number of individuals, including JDRFs Chief Financial Officer and Director of Accounting and Finance, the Chief Executive Officer, other executives, its external senior tax advisor and others as necessary to ensure accuracy. Any questions and changes with respect to the draft return are addressed. Following this process, the return is reviewed by JDRFs Audit Committee of the Board of Directors with its outside tax advisors. Once approved, the return is distributed to all members of JDRFs Board of Directors for review and comment before it is filed with the Internal Revenue Service. UPDATED BYLAWS, FORM 990,PART VI, PAGE 6, QUESTION 4 ON APRIL 14, 2016 JDRF AMENDED AND MADE SIGNIFICANT CHANGES TO ITS BYLAWS. CHANGES THAT WERE MADE INCLUDE PROVISIONS ON FORMATION AND CLOSING OF CHAPTERS; AND UPDATED TERM LIMITS OF BOARD MEMBERS, OFFICERS, CHANCELLORS, AND COMMITTEE MEMBERS. THE BYLAW AMENDMENTS ALSO REDEFINE JDRF BOARD COMMITTEES AND THEIR RESPONSIBILITIES. JDRF THERAPEUTICS FUND LLC C/O JDRF - 26 BROADWAY 14TH FLOOR NEW YORK NY 10004 274967989 INVESTMENT DE 234670 JDRF CHARITABLE REMAINDER TRUST (5) ANNUITY PA false